Background: Chronic kidney disease (CKD) has been linked to higher heart failure (HF) risk. Anemia is a common consequence of CKD, and recent evidence suggests that anemia is a risk factor for HF.

Study findings support the monitoring and management of iron status in patients with early stages of chronic kidney disease (CKD).

Michael Bromberg, MD, PhD, talks with Physician’s Weekly about renal disease in patients with paroxysmal nocturnal ...

We observed that anemia and chronic kidney disease are two frequent conditions among stroke patients. Anemia was independently associated with a decreased one-year survival. Although GFR was ...

Despite finally winning a hard-fought FDA approval for its chronic kidney disease (CKD) anemia drug Vafseo last year, Akebia ...

In a 2024 clinical practice guideline issued by the Kidney Disease: Improving Global Outcomes (KDIGO) organization, a ...

Strong results to date of Vafseo U.S. launch; expect Vafseo Q1 2025 net product revenues of approximately $10-$11 millionCash resources and cash ...

Butler, Chief Executive Officer of Akebia said: “We believe Vafseo can be a new standard of care for the treatment of anemia due to chronic kidney disease (CKD). The U.S. product launch is ...